Auris Medical (EARS) Provides Update on Bentrio Program in Allergy
- Wall Street ekes out gains to close languid week
- 'Faster than Porsche but Safer than Volvo': Tesla (TSLA) Begins Model S Plaid Deliveries, Priced Between $131,100 and $145,600
- Oil hits multi-year highs in third weekly gain on demand recovery
- Snowflake (SNOW) Falls Following Investor Day Despite Strong Guidance, Analysts Bullish But Say Investors May Have Wanted More
- Dollar looks stronger as euro and sterling dip
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
- BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitis
- Clinically relevant and significant reduction in nasal symptoms
- Superior efficacy ratings by patients and clinicians
- Pre-submission meeting with FDA supports 510(k) regulatory pathway
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced additional details on the outcomes from the clinical investigation of its BentrioTM nasal spray in allergic rhinitis and provided an update on the regulatory pathway in the US for the intended use in allergy.
BentrioTM effectively alleviates allergy symptoms in clinical pollen challenge
BentrioTM was tested in an open-label randomized cross-over trial in 36 patients with allergic rhinitis to grass pollen. Study participants were administered a single dose of BentrioTM nasal spray or a comparator product prior to controlled pollen exposure for four hours in an allergen challenge chamber. The challenge was repeated with the alternate treatment following a wash-out period. The study demonstrated a rapid onset and long durability of Bentrio’s protective effect, established substantial equivalence to the marketed comparator with superior efficacy ratings by patients and clinicians, and showed good tolerability.
Under treatment with BentrioTM, participants reported a mean increase in the Total Nasal Symptom Score (TNSS; averaged over 4 hours in 20 minute intervals) of 4.75 points, which was 1.11 points and thus significantly below TNSS levels when exposed to pollen without nasal spray protection (ANCOVA least square means; 95% confidence interval, CI: -1.61 to -0.61). A 1-point reduction in the TNSS is considered clinically relevant. 31.4% of study participants rated the efficacy of BentrioTM as “good” or “very good”, while study investigators provided such rating for 45.7% of participants. Under treatment with the comparator product, a powder spray based on hydroxypropylmethylcellulose (HMPC), the TNSS increased on average by 5.14 points, which was 0.71 points lower than when unprotected (CI: -1.21 to -0.21). 14.3% of study participants rated the efficacy of the comparator as “good” or “very good”, while study investigators provided such rating for 25.0% of participants. BentrioTM showed significantly lower increases in the TNSS than HPMC especially during the early phase of pollen exposure, reaching clinical relevance and suggesting a rapid onset of action.
As previously announced, BentrioTM met the primary endpoint of substantial equivalence in the change of TNSS relative to HPMC, which serves as a predicate device for the planned 510(k) submission to the US Food and Drug Administration (FDA). Final analyses show a difference of 0.4 points in favor of BentrioTM (CI -0.89 to 0.10), confirming non-inferiority. Proof of substantial equivalence to the predicate device is a key requirement for market clearance in the US under the 510(k) regulatory pathway. In addition, the study provided further evidence for the favorable safety profile of BentrioTM; with the exception of one case, all study participants rated the tolerability favorably.
Pre-submission meeting with FDA
On May 6, 2021, Altamira Medica met with the FDA for a pre-submission meeting relating to a 510(k) pre-market notification application. The Company expects to request regulatory clearance for BentrioTM for the intended use in allergy under the 510(k) pathway. During the meeting, the Company obtained important information needed to help finalize the submission package. Importantly, the Agency indicated that the design of the pollen challenge study appeared appropriate to support the planned 510(k) submission.
“We are very delighted to have reached further important milestones with our BentrioTM program”, commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “We are very delighted by the positive outcomes from the pollen chamber study, where BentrioTM provided rapid and effective protection for four hours of challenging allergen exposure. In addition, we very much appreciated the FDA’s feedback during the pre-submission meeting and feel well positioned to advance the preparations for a 510(k) submission. At the same time, we are on track to meet the essential requirements for marketing the product in Europe under the CE mark shortly. We intend to launch the commercialization of BentrioTM in selected European countries towards the end of June 2021 through various on- and offline distribution channels. Launch preparations are in full swing.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sorrento Therapeutics (SRNE) Receives Authorization From the UK Regulatory Agency to Conduct a Phase 2 Clinical Trial for COVI-DROPS in an Outpatient Setting
- Quidel Corp (QDEL) Receives Amended EUA for New Sofia Q Rapid Antigen Test Device
- CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!